Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments. The study published in the International Journal of Molecular Science and led by Goll-Ohio Eminent Scholar and distinguished professor John J. Kopchick, Ph.D., and his graduate student Arshad Ahmad at the Heritage College of Osteopathic Medicine, found that blocking the growth hormone receptor may help make lung cancer treatments more effective.

Cells have to break down sugar to produce energy. In most organisms, this process of glycolysis takes place in the cytosol. This is not the case with trypanosomes. These possess specialized organelles called glycosomes where glycolysis takes place. “Because the parasites rely fundamentally on these organelles for energy production, any disruption of glycosome biogenesis is lethal to them,” says Erdmann.

Daily aspirin use does not offer a quick or reliable way to prevent bowel cancer in the general population and carries immediate risks of serious bleeding, a new Cochrane review finds.

Bowel cancer, also known as colorectal cancer, is one of the most common types of cancer worldwide. Prevention typically involves following a healthy lifestyle and periodically undergoing routine screening tests.

Scientists have developed an adaptable materials platform that can safely and efficiently deliver a wide range of genetic medicines, a breakthrough that could accelerate the development of next‑generation vaccines, cancer treatments, and gene‑silencing drugs.

Experts from the University of Nottingham’s School of Pharmacy have created a new drug delivery platform that uses modular building blocks that self‑assemble with Ribonucleic acid- RNA to form nanoscale delivery particles.

Researchers from Tokyo Metropolitan University have created a new molecule which carries DNA into biological cells, to treat or vaccinate against illnesses. Many existing options rely on molecules with a strong positive charge, which can cause harmful inflammation. The team overcame this by using a neutral molecule and a new method to bind DNA to it, making it possible to deliver DNA into cells.

Industrial yeasts are a powerhouse of protein production, used to manufacture vaccines, biopharmaceuticals, and other useful compounds. In a new study, MIT chemical engineers have harnessed artificial intelligence to optimize the development of new protein manufacturing processes, which could reduce the overall costs of developing and manufacturing these drugs.

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation based on results from the global Phase 3 BREAKWATER trial (NCT04607421).

New antibody-drug conjugates (ADCs) developed at Institute of Science Tokyo combine a CD4 mimic with neutralizing antibodies for enhanced suppression of human immunodeficiency virus (HIV) infection. By targeting the gp120 on the viral envelope via a two-step mechanism, the ADCs effectively block viral entry - offering seven times better efficacy than existing approaches.

Bioengineered E. coli bacteria can now produce a group of compounds with anticancer, anti-HIV, antidiabetic and anti-inflammatory activities. The Kobe University achievement is the result of a rational design strategy that yields a platform for the industrial production of drug candidates.

Plants produce many substances with promising pharmacological activities. For example, Rhododendron species produce a class of compounds, called orsellinic acid-derived meroterpenoids, with remarkable anticancer, anti-HIV, antidiabetic and anti-inflammatory activities.

A new study published by Mayo Clinic researchers suggests that ovarian cancer cells quickly activate a survival response after PARP inhibitor treatment, and blocking this early response may make this class of drugs work better.

PARP inhibitors are a common treatment for ovarian cancer and can be especially effective in cancers with impaired DNA repair.

Immutep Aces Phase IIb in First-Line Head and Neck Cancer, Eyes Regulatory Path Ahead 7/12/2024

Senate Unanimously Passes Bill to Reduce Big Pharma Patent Thickets, Increase Competition 7/12/2024

AbbVie’s Humira Continues to Lose Market Share as Biosimilars Gain Ground: Report 7/12/2024

Akebia Ends Deal With CSL Vifor, Unveils Hefty Price Tag for CKD Anemia Drug Vafseo 7/12/2024

PBMs and Big Pharma Play Blame Game for Inflated Prescription Drug Prices 7/12/2024

Biopharma Layoff Tracker 2024: Spark, Novartis, Indivior and More Cut Staff 7/12/2024

FDA Decision Tracker: Novo’s Once-Weekly Insulin Icodec Rejected 7/12/2024

EMA Finds No Link Between GLP-1 Drugs and Suicidal Thoughts, Self-Harm 4/12/2024

EC Approves Illumina’s Plan to Divest Cancer Diagnostics Maker Grail 4/12/2024

AACR, Cancer Treatment and the Promise of Antibody-Drug Conjugates 4/12/2024